Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Adagio Therapeutics (Nasdaq: ADGI) announced that CEO Tillman Gerngross will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 7:30 a.m. ET. A live webcast will be available on the company’s investor website and will be archived for 60 days.

Adagio focuses on developing antibody-based treatments for infectious diseases, including COVID-19 and influenza. The company aims to provide effective and affordable solutions, emphasizing broad accessibility to their therapies.

WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that Tillman Gerngross, Ph.D., chief executive officer of Adagio, is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30 a.m. ET.

A live webcast will be available in the investor section of the company's website at investors.adagiotx.com and will be archived for 60 days following the presentations.

About Adagio Therapeutics

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with the potential for a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple non-competing, broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch, if authorized or approved by regulatory authorities, ensuring the potential for broad accessibility to people around the world. For more information, please visit www.adagiotx.com.

Contacts:

Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com  

FAQ

When will the Adagio Therapeutics CEO present at the J.P. Morgan Healthcare Conference 2022?

Tillman Gerngross, CEO of Adagio Therapeutics, will present on January 13, 2022, at 7:30 a.m. ET.

How can I watch the Adagio Therapeutics presentation at the J.P. Morgan Healthcare Conference?

The presentation will be available via a live webcast on Adagio Therapeutics' investor website.

What are the main focuses of Adagio Therapeutics?

Adagio Therapeutics focuses on developing antibody-based solutions for infectious diseases, particularly COVID-19 and influenza.

What is the significance of ADG20 for Adagio Therapeutics?

ADG20 is a leading antibody in Adagio's portfolio, designed for broad neutralization against SARS-CoV-2.

Where can I find more information about Adagio Therapeutics?

More information is available on their website at www.adagiotx.com.